Offers Canadians Access to International Innovation and Expertise through Exclusive Partnership
MARKHAM, ON, Feb. 25, 2014 /CNW/ - MedReleafTM, a Canadian-owned and operated company, has been approved as a licensed producer under Health Canada's new Marihuana for Medical Purposes Regulations. With this license, MedReleaf is authorized to supply cannabis for medical purposes to patients across the country.
MedReleaf is the only licensed producer to have an exclusive partnership with world-renowned medical cannabis innovator, Tikun Olam, the largest government-approved producer of medical cannabis in Israel. Through this partnership, patients will have a wide variety of product to choose from including a dozen of Tikun Olam's proprietary varieties, all locally grown at MedReleaf's facility in Markham, Ontario. These proprietary varieties will include Tikun Olam's well-regarded Avidekel™ that is known to contain high levels of CBD and very low levels of THC.
"Our partnership with Tikun Olam provides us with access to exclusive strains as well as treatment data on more than 7,000 patients," said Neil Closner, Chief Executive Officer at MedReleaf. "This proprietary data provides us with a solid understanding of the effectiveness and efficacy of different medical cannabis varieties on patients."
Together, MedReleaf and Tikun Olam will spearhead studies that examine the effectiveness of these varieties in the treatment of various conditions such as nausea, vomiting and weight loss associated with cancer treatment and chronic pain associated with rheumatoid arthritis, fibromyalgia, multiple sclerosis, post-operative recovery, HIV/AIDS, Huntington's and Parkinson's disease, inflammatory bowel disease, glaucoma and arthritis as well as Tourette's syndrome, epileptic seizures and other neurological disorders.
"Our focus is on evidence based clinical research to validate the benefits of medical cannabis on a wide range of conditions and symptoms, allowing physicians to ultimately provide individualized care to their patients," said Closner. "We are currently looking to partner with Canadian physicians on new research initiatives."
MedReleaf's senior leadership team has more than 100 years of combined experience working with cannabis and treating patients. MedReleaf also has Patient Care Coordinators available -highly qualified healthcare professionals who will work with MedReleaf patients to recommend the strain (or strains) that best meet their therapeutic needs. These Patient Care Coordinators will also be an essential support resource for physicians to help them more easily and accurately assist their patients.
"Our goal is for MedReleaf to be recognized as a key player in the Canadian healthcare industry and to be the most trusted and reliable producer of medical grade cannabis in the country," added Closner. "We have industry leading quality control and proven patient protocols matched with proprietary strains that can't be found anywhere else."
Canadian patients can now sign-up with MedReleaf at www.medreleaf.com
MedReleafTM is a Canadian-owned and operated producer and distributor of medical grade cannabis. The company operates a 55,000 square foot state-of-the-art facility in Markham, Ontario. Its leadership team consists of highly skilled and expert professionals who have more than 100 years of combined experience treating patients and working with cannabis. They have extensive backgrounds in business, molecular plant genetics, biotechnology, horticulture, clinical laboratory management and operations. MedReleaf is dedicated to improving the quality of life for patients across the country by providing them with a broad range of the finest quality varieties anywhere in the world. MedReleaf obtained its license from Health Canada in February 2014.
Image with caption: "MedReleaf Logo (CNW Group/MedReleaf Corp.)". Image available at: http://photos.newswire.ca/images/download/20140225_C7098_PHOTO_EN_37115.jpg
SOURCE: MedReleaf Corp.
For further information:
GoldFenix Communications & Associates
GoldFenix Communications & Associates